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Testosterone is an important hormone for both bone gain and maintenance in men. Hypogonadal men have accelerated bone
turnover and increased fracture risk. In these men, administration of testosterone inhibits bone resorption and maintains bone
mass. Testosterone, however, is converted into estradiol via aromatization in many tissues including male bone. The importance
of estrogen receptor alpha activation as well of aromatization of androgens into estrogens was highlighted by a number of cases of
mensuﬀeringfromaninactivatingmutationintheestrogenreceptoralphaorinthearomataseenzyme.Allthesementypicallyhad
low bone mass, high bone turnover and open epiphyses. In line with these ﬁndings, cohort studies have conﬁrmed that estradiol
contributes to the maintenance of bone mass after reaching peak bone mass, with an association between estradiol and fractures
in elderly men. Recent studies in knock-out mice have increased our understanding of the role of androgens and estrogens in
diﬀerent bone compartments. Estrogen receptor activation, but not androgen receptor activation, is involved in the regulation of
male longitudinal appendicular skeletal growth in mice. Both the androgen and the estrogen receptor can independently mediate
the cancellous bone-sparing eﬀects of sex steroids in male mice. Selective KO studies of the androgen receptor in osteoblasts in
male mice suggest that the osteoblast in the target cell for androgen receptor mediated maintenance of trabecular bone volume
and coordination of bone matrix synthesis and mineralization. Taken together, both human and animal studies suggest that
testosterone has a dual mode of action on diﬀerent bone surfaces with involvement of both the androgen and estrogen receptor.
1.Introduction
The major circulating androgen in men is testosterone.
Testosterone, like adrenal androgens, is a C19 steroid
synthesized from cholesterol. Both gonadal and adrenal
testosterone can be converted into estrogens (C18 steroids)
by the P 450 aromatase, encoded by CYP 19, which is
present in many peripheral tissues, including bone. Bone
cells express androgen receptor (AR) as well as estrogen
receptor-α (ERα)a n d– β (ERβ)[ 1]. Therefore, androgen
action on male bone may be explained by AR activation or,
alternatively, activation of ERα and –β (Figure 1).
2. Evidence from Human Studies
The importance of estrogen receptor alpha activation as
well as of aromatization of androgens into estrogens was
highlighted by a number of cases of men suﬀering from an
inactivatingmutationintheestrogenreceptoralphaorinthe
aromatase enzyme [2–4].
Table 1 shows the age of diagnosis, bone phenotype,
and eﬀect of estrogen treatment (if appropriate) in these
men. All these men had low bone mass as measured
by DEXA, high bone turnover, and open epiphyses and
the distal radius despite normal to elevated testosterone
concentrations. Estrogen treatment resulted in closure of
the epiphyses, increased bone density, and reduced bone2 Journal of Osteoporosis
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Figure 1: Metabolism of sex steroids. (i) Testosterone (T), that is secreted by the testes, can directly act on its receptor, the androgen receptor
(AR), present in bone cells. (ii) T can also be converted locally to dihydrotestosterone (DHT) by 5α-reductase. (iii) In addition, T can
undergo aromatization to 17β-estradiol (E2) by aromatase. E2 acts on one or both estrogen receptors (ERα or ERβ). (iv) The adrenals
secrete C19 androgens including dehydroepiandrosterone (DHEA) that can also be converted to (v) estrone (E1) and E2 by aromatase,
17β-hydroxysteroid dehydrogenase (17β-HSD), and 3β-HSD or to T by 17β-HSD and/or 3β- H S D .( v i )I nm e na n dw o m e n ,Ta n dE 2 are
predominantly bound to sex hormone binding globulin (SHBG), synthesized by the liver.
turnover. One patient diagnosed at much younger age was
followed by peripheral computerized tomography during
estrogen treatment over a period of three years. During
estrogen treatment, the cortical area expanded as a result of
periosteal expansion. There was no eﬀect on trabecular bone
density suggesting that the main action of estrogen on male
growing bone is on the cortical and not the cancellous com-
partment [5]. However, it has been suggested that trabecular
bone may require higher levels for its regulation. For cortical
bone, estrogen deﬁciency is the major cause of age-related
bone loss [6]. It is clear, therefore, that estrogen is important
for epiphyseal closure as well as periosteal bone formation
and hence cortical bone mineral acquisition during male
growth. Observations in a single patient suﬀering from
an inactivating mutation in the androgen receptor suggest
that estrogen may also increase mineral apposition at the
endocortical surface [7]. During adult life, estrogens mediate
endosteal bone apposition and volumetric bone density,
without marked inﬂuence on periosteal bone apposition.
The ﬁnding of a bone size intermediate between male
and female supports a role for testosterone as an essential
mediator for periosteal bone expansion, but not as the sole
stimulus for bone expansion during growth, supporting the
concept that estrogen is also involved in bone maintenance
after growth in men.
Table 2 shows cohort studies in men in which both estra-
diol and testosterone were measured, with either tandem
mass spectrometry (LC-MS-MS) or with immunoassay, and
in relation to bone loss and fractures [8–12]. Most but not all
(Dubbo Osteoporosis Epidemiology study) of these studies
showed an association between estradiol and fractures in
elderly men [14].
While serum estradiol and testosterone are inversely
related to fracture risk in older men, serum-sex-hormone
binding globulin (SHBG) shows a positive relationship. Low
serum estradiol, low serum testosterone, and high SHBG
predict clinical vertebral fractures, nonvertebral osteoporosis
fractures, and hip fractures. For estradiol, a threshold eﬀect
has been documented, below which estradiol is related to
fracture risk [13]. Low estradiol induces bone resorption
independently of testosterone, presumably reﬂecting a net
increase in endocortical bone resorption [15, 16].
The eﬀect of estrogen on bone resorption was illustrated
byadministrationofanaromataseinhibitortomenreceiving
a GnRH agonist in combination with testosterone, resulting
in increased bone resorption markers (deoxypyridinoline,
N-telopeptide of type I collagen). Bone resorption markers
increased signiﬁcantly in the absence of both testosterone
and estrogen and were unchanged in men receiving both
hormones. Estrogen prevented the increase in the bone
resorption markers, whereas testosterone had no signiﬁcant
eﬀect. By contrast, serum osteocalcin, a bone formation
marker, decreased in the absence of both hormones, and
both estrogen and testosterone maintained osteocalcin lev-
els. Taken together, according to this one study in men,
estrogen may be important in regulating bone resorption,Journal of Osteoporosis 3
Table 1: Clinical parameters of men with aromatase deﬁciency or estrogen resistance.
Aromatase deﬁciency Estrogen resistance
Age of diagnosis Newborn, 24–38yrs 28.5yrs
Bone phenotype
(i) Persistent linear growth (i) Continuing linear growth into
adulthood
(ii) Unfused epiphyseal cartilages (ii) Unfused epiphyses
(iii) Delayed bone age (iii) Delayed bone age
(iv) Osteopenia/osteoporosis (iv) Osteoporosis
(v) Eunuchoid proportion of the skeleton (v) Progressive genu valgum
(vi) Progressively worsening of bilateral
genu vagum
(vi) Eunuchoid proportions of the
skeleton
Hormonal analysis
(i) Serum estradiol below the range of
detection
(i) High concentration of serum
estradiol, estrone, FSH, LH
(ii) Gonadotropins and circulating
testosterone ranging from normal to
elevated
(ii) Normal serum testosterone
(iii) Impaired glucose metabolism
(iv) Insulin resistance
Eﬀect of estrogen treatment
(i) Complete epiphyseal closure No changes
(ii) Spinal BMD increase
(iii) Skeletal maturation
Table 2: Overview of cohort studies in men.
Average
age of men
Number
of men
Study
duration
LC-MS-
MS Immunoassay Main result
Rancho Bernardo
study [8] 66 352 12yr x (i) E: strong correlation with fractures
(ii)T: no correlation with fractures
Dubbo study [9] >60 609 16yr x (i) T: no correlation with fractures
(ii) E: strong correlation with fractures
Tromso [10] 50–84 1364 8.4yr x T, E, SHBG: no correlation with fractures
Rotterdam study
[11] 67.7 ± 6.8 178 6.5yr x T, E, SHBG: no correlation with fractures
Framingham study
[12] 71 793 18yr x (i) E: strong correlation with fractures
(ii)T+E:strongcorrelationwithfractures
MrOS study [13] 75 2639 3.3yr x E, SHBG: strong correlation with frac-
tures
E: estrogen; T: testosterone; SHBG: sex hormone binding globulin.
whereas estrogen and testosterone may both be important
in maintaining bone formation [17]. Another study in
younger men, however, concluded that both androgens
and estrogens play independent and fundamental roles in
regulating bone resorption. In this study, young men (20–
44yrs) were divided in 3 groups. The ﬁrst group received
only a GnRH analog, the second group a GnRH analog plus
testosterone, and the third group a GnRH analog plus an
aromatase inhibitor. Bone resorption markers increased in
the group who received a GnRH analog alone and the group
who received a GnRH analog plus an aromatase inhibitor.
Bone formation markers increased more in the ﬁrst group
than in the second group. Overall, these ﬁndings suggest
that both estrogens and androgens play independent and
fundamentalrolesinregulatingboneresorptioninmen.This
study also suggests that androgens may play an important
roleintheregulationofboneformationinmen[18].Genetic
polymorphism in the Cyp 19 or in ESR genes, encoding for
aromatase and estrogen receptor, respectively, may further
mediate the risk for bone loss induced by low estradiol in
men [19].
In humans, in contrast to rodents, circulating testos-
terone and estradiol are bound to sex-hormone-binding
globulin, with testosterone more tightly bound than estra-
diol. The role of free (not bound to any protein) or
bioavailable (not bound to SHBG) versus total testosterone
remains controversial [20]. SHBG, which increases with age,
has been associated with bone loss in elderly men [21].
However,otherstudiesinyoungermenhaveshownapositive
rather than a negative association between peak bone mass4 Journal of Osteoporosis
Table 3: Relative eﬀects of testosterone, dihydrotestosterone, estradiol, and selective estrogen receptor modulator on body weight,
appendicular skeletal growth, cancellous bone mass, and on cortical bone area.
Body weight gain Appendicular skeletal growth Cancellous bone mass Cortical bone area
Orch + T =,↑ =, ↑↑ ↑
Orch + DHT =,↓ =,↑↑ =, ↑
Orch + E2 =, ↓ = ↑ =, ↑
Orch + SERM ↓ NA ↑↑
Orch: orchidectomy; T: testosterone; DHT: dihydrotestosterone; E2: estradiol; SERM: selective estrogen receptor modulator.
andSHBG[22–24].However,theexactroleandcontribution
ofSHBGinbonegainandlossinmenremainstobeclariﬁed.
Compared to estradiol levels (see Table 1), testosterone
concentrations are less consistently associated with bone
loss/fractures in men, except for very low levels in hypogo-
nadal men (especially men following chemical and surgical
castration) who show a signiﬁcant increase in bone turnover,
bone loss, and fracture risk [25]. In these men, testosterone
inhibits bone resorption and maintains bone mass [26]
whereas its eﬀect in elderly men with borderline low
testosterone or low normal testosterone concentrations is
more controversial [27].
With selective estrogen receptor modulators (SERM’s),
very few data are currently available in men. In one study
in men receiving a GnRH agonist for prostate cancer,
raloxifene increased bone mineral density of the hip and,
to a lesser degree, the spine. In this study, Raloxifene
reduced serum concentrations of aminoterminal propeptide
of type I collagen, a marker of bone formation and also
tended to reduce urinary excretion of deoxypyridinoline, a
marker of bone resorption [28]. Short-term administration
(12 weeks) of an aromatase inhibitor in elderly men was
found to increase testosterone and reduce estrogen levels
b u tw i t hh a r d l ya n ye ﬀect on bone metabolism [29]. This
lack of an eﬀect may be due to the concomitant increase
in testosterone production, the relative modest eﬀect on
estradiol production, or a combination of both factors.
However when the aromatase inhibitor was administered
for a longer term (12 months) there was a decrease in
bone mineral density [30]. Therefore, aromatase inhibition
does not improve skeletal health in aging men with low or
normal testosterone levels. With selective androgen receptor
modulators (SARMs), capable of selectively stimulating the
androgen receptor in bone and muscle but not in prostate,
no clinical bone data are available in men [31].
3. Evidence from Animal Studies
To further investigate the relative importance of androgen
receptor-mediated testosterone actions compared to estra-
diol eﬀects, an increasing number of animal experiments
have been published, in particular in the orchidectomized
rodent, a well-characterized model for hypogonadal osteo-
porosis. Following orchidectomy, bone resorption increases
atcancellousandendocorticalsurfacesandresultsinreduced
cancellous and cortical bone volume. Periosteal bone forma-
tion during growth is decreased in orchidectomized rodents
as well and further lowers bone strength [1]. A number of
animal experiments have investigated the bone phenotypic
changes induced by androgens, nonaromatisable androgens
and estrogens in orchidectomized rodents (mice, rat and
growing/non-growing). Table 3 shows the relative eﬀects of
androgens [32–34], non-aromatisable androgens [32–36],
estrogens [33, 36, 37] on bone turnover, bone density, and
periosteal bone formation in male orchidectomized rats.
From these studies, it is clear that non-aromatisable
androgens can also stimulate periosteal bone formation and
inhibit cancellous bone, although less than testosterone,
a n dt h a te s t r a d i o le x e r t sp o t e n te ﬀects on diﬀerent bone
surfaces [36]. However, what is not always clear is to what
extent the eﬀects of these hormones are pharmacological or
physiological and, if physiological, to what extent the eﬀects
can be extrapolated to the human condition, in a context of
higher estradiol concentrations than in mice [38].
Other animal experiments have investigated the bone
phenotype of transgenic male animals with KO of AR
(ArKO), ER alpha (ERKO), beta (BERKO), or both
(DERKO), and this in combination with orchidectomy with
or without replacement with androgens and estrogens. The
latter is needed because the ArKO and ERKO models may
have an impact on respective concentrations of andro-
gens/estrogens [26, 39]( Table 4). Overall, available evidence
from these studies suggests that, ER activation, not AR
activation, is involved in the regulation of male longitudinal
appendicular skeletal growth in mice. ERα and AR but not
ERβ enhance cortical radial bone growth. The AR, not Erβ,
is required for the maintenance of cancellous bone mass.
AR and ERα,b u tn o tE R β, can independently mediate the
cancellous bone-sparing eﬀects of sex steroids in male mice
[26].
These studies have greatly increased our understanding
of the role of estrogen receptor and androgen receptors
in male skeletal growth and maintenance in male rodents.
Both AR and ERα are involved in male skeletal growth
and maintenance, supporting a dual mode of action for
testosterone, either directly on the AR or indirectly on the
ERα through aromatization.
In summary, both AR and ERα activation appear to
stimulate periosteal bone formation and cortical bone
growth. ERα is also involved in longitudinal bone formation
but its action on periosteal surface as well as growth plate
may be mediated indirectly by the GH-IGF-I axis [40]. On
trabecular bone surfaces, AR activation may be most critical,
at least in mice, as elegantly illustrated with a double KOJournal of Osteoporosis 5
Table 4: Summary of the skeletal phenotypes in mice with diﬀerent sex steroid-related gene inactivations.
Cancellous bone
Longitudinal skeletal growth Cortical bone area Intact mice Eﬀe c to fEi nO r c h E ﬀect of T in Orch Eﬀe c to fD H Ti nO r c h
BERKO 0 0 0 Yes ND Yes
ERKO −− +N o Y e s Y e s
DERKO −− +N o N D Y e s
ArKO −− − Yes ND ND
Tfm ? ? − Yes Partial ND
+: Increased; −: decreased; 0: no eﬀect; conﬂicting results; ND: not determined; Orch: orchidectomy; E: treatment with physiological levels of estrogen; T:
treatment with physiological of testosterone; DHT: treatment with physiological levels of 5α-dihydrotestosterone.
Table 5: Overview bone parameters in osteoblast-speciﬁc AR knockout mice.
Tb. N
(/mm)
Tb. Th
(μm)
BV/TV
(%)
Osteoid surface
(%BS)
OCL surface
(%BS)
MAR
(μm/day)
BFR
(μm2 /μm/day)
Col 2.3-cre AR KO ↓↑↓ == = =
Osteocalcin-cre KO ↓↓↓ ↑ == =
Tb.N:trabecularnumber;Tb.Th:trabecularthickness;BV/TV:trabecularbonevolume;OCL:osteoclast;MAR:mineralappositionrate;BFR:boneformation
rate.
AR-ER in comparison with either AR or ERα disruption
alone. Combined AR and ERα inactivation further reduced
cortical bone and muscle mass and AR activation was
found to be solely responsible for the development and
maintenance of male trabecular bone mass. However, both
AR and ERα activation appeared to be essential to optimize
the acquisition of cortical bone and muscle mass [41]. Erβ,
on the other hand, seems not to be relevant for bone
growth and maintenance in male mice [42]. To further
document the target cell of AR and ER in mice, the AR
was recently selectively knockedout in bone cells by cre-
lox technology. In two studies (Table 5), the osteoblast was
targeted which resulted in a trabecular and no cortical
phenotype, suggesting that the osteoblast is the target cell
for androgen-receptor-mediated maintenance of trabecular
bone volume and coordination of bone matrix synthesis and
mineralization [43, 44].
This assumption was further supported by a cocul-
ture experiment were the in vitro osteoclastogenesis was
assessed using osteoclast precursor cells from bone marrow
and calvaria osteoblasts from male WT and ARKO mice.
When the AR was absent in osteoclast precursor cells,
osteoclastogenesis was unaﬀected [45]. Osteoclastogenesis,
in response to 1α,25(OH)2D3 after activation by RANKL
and M-CSF (macrophage-colony stimulating factor), also
seemed unaﬀected in AR-deﬁcient osteoclasts. However, AR
inactivation in osteoblasts potentiated osteoblastic functions
that promote osteoclastogenesis in the presence of inducers.
RANKL turned out to be upregulated in these AR-deﬁcient
osteoblasts, suggesting that the suppressive function of AR
on RANKL gene expression mediates the protective eﬀects of
androgens on bone remodelling through inhibition of bone
resorption. It would seem therefore that intact AR function
is required for the suppressive eﬀects of androgens on the
osteoclastogenesis supporting activity of osteoblasts, but not
osteoclasts [45].
In conclusion, both human and animal experiments
suggest that testosterone has a dual mode of action on
diﬀerentbonesurfaces.ActivationofbothERαandARseems
to be involved.
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